Spyre Therapeutics (AGLE) Stock Forecast, Price Target & Predictions
AGLE Stock Forecast
Spyre Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
AGLE Analyst Ratings
According to 2 Wall Street analysts, Spyre Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AGLE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2022 | Wells Fargo | Equal-Weight | Overweight | Upgrade |
| Oct 27, 2022 | Piper Sandler | Neutral | Overweight | Upgrade |
| Aug 09, 2022 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
Spyre Therapeutics's last stock rating was published by Wells Fargo on Oct 28, 2022. The company Upgrade its AGLE rating from "Equal-Weight" to "Overweight".
Spyre Therapeutics Financial Forecast
Spyre Therapeutics Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $688.00K | $198.00K | $168.00K | $174.00K | $625.00K | $1.36M | $1.40M | $13.70M | - | - | - | - | - | - | - | $2.38M | $1.51M | $1.26M | $1.48M | $982.00K | $1.15M | $1.37M | $859.00K |
| Avg Forecast | $1.55M | $1.38M | $1.09M | $5.50M | $3.54M | $721.05K | $120.00K | $5.00M | $3.79M | $570.00K | $1.24M | $4.05M | $12.15M | $13.00M | $4.54M | $4.54M | $3.52M | $3.40M | $3.10M | $2.76M | $1.96M | $1.36M | $1.44M | $1.51M | $982.00K | $1.34M | $1.25M | $10.13M |
| High Forecast | $1.86M | $1.65M | $1.30M | $6.60M | $4.25M | $865.26K | $144.00K | $6.00M | $4.54M | $684.00K | $1.49M | $4.86M | $14.58M | $15.60M | $5.45M | $5.45M | $4.23M | $4.08M | $3.72M | $3.31M | $2.36M | $1.63M | $1.73M | $1.81M | $1.18M | $1.61M | $1.50M | $12.16M |
| Low Forecast | $1.24M | $1.10M | $868.50K | $4.40M | $2.83M | $576.84K | $96.00K | $4.00M | $3.03M | $456.00K | $993.46K | $3.24M | $9.72M | $10.40M | $3.63M | $3.63M | $2.82M | $2.72M | $2.48M | $2.21M | $1.57M | $1.08M | $1.16M | $1.21M | $785.60K | $1.08M | $1.00M | $8.11M |
| # Analysts | 7 | 7 | 15 | 16 | 16 | 20 | 9 | 12 | 17 | 14 | 6 | 11 | 7 | 7 | 9 | 15 | 13 | 13 | 13 | 7 | 7 | 7 | 9 | 9 | 9 | 8 | 8 | 10 |
| Surprise % | - | - | - | - | - | 0.95% | 1.65% | 0.03% | 0.05% | 1.10% | 1.10% | 0.35% | 1.13% | - | - | - | - | - | - | - | 1.21% | 1.11% | 0.87% | 0.98% | 1.00% | 0.85% | 1.10% | 0.08% |
Spyre Therapeutics's average Quarter revenue forecast for Sep 23 based on 16 analysts is $3.54M, with a low forecast of $2.83M, and a high forecast of $4.25M. AGLE's average Quarter revenue forecast represents a 414.62% increase compared to the company's last Quarter revenue of $688.00K (Jun 23).
Spyre Therapeutics EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 7 | 15 | 16 | 16 | 20 | 9 | 12 | 17 | 14 | 6 | 11 | 7 | 7 | 9 | 15 | 13 | 13 | 13 | 7 | 7 | 7 | 9 | 9 | 9 | 8 | 8 | 10 |
| EBITDA | - | - | - | - | $-18.34M | $-159.25M | $-18.81M | $-18.78M | $-18.35M | $-22.05M | $-24.04M | $-19.87M | $-6.34M | $-17.86M | $-18.57M | $-21.39M | $-21.47M | $-17.91M | $-17.07M | $-11.84M | $-9.34M | $-8.05M | $-7.80M | $-6.57M | $-6.20M | $-6.20M | $-5.40M | $-4.52M |
| Avg Forecast | $-309.60K | $-275.20K | $-19.13M | $5.49M | $-16.17M | $-31.36M | $-20.46M | $4.99M | $-17.30M | $-24.79M | $-21.88M | $-18.50M | $9.05M | $12.71M | $-21.19M | $4.53M | $3.35M | $3.35M | $3.09M | $2.65M | $-7.37M | $-7.13M | $-8.80M | $-6.71M | $-6.20M | $-7.11M | $-4.88M | $-53.29M |
| High Forecast | $-371.52K | $-330.24K | $-15.30M | $6.58M | $-12.94M | $-25.09M | $-16.37M | $5.99M | $-13.84M | $-19.83M | $-17.50M | $-14.80M | $10.86M | $15.25M | $-16.95M | $5.44M | $4.02M | $4.02M | $3.71M | $3.18M | $-5.90M | $-5.71M | $-7.04M | $-5.37M | $-4.96M | $-5.69M | $-3.91M | $-42.63M |
| Low Forecast | $-247.68K | $-220.16K | $-22.95M | $4.39M | $-19.41M | $-37.63M | $-24.55M | $3.99M | $-20.76M | $-29.75M | $-26.26M | $-22.20M | $7.24M | $10.17M | $-25.43M | $3.63M | $2.68M | $2.68M | $2.47M | $2.12M | $-8.85M | $-8.56M | $-10.56M | $-8.05M | $-7.43M | $-8.53M | $-5.86M | $-63.95M |
| Surprise % | - | - | - | - | 1.13% | 5.08% | 0.92% | -3.76% | 1.06% | 0.89% | 1.10% | 1.07% | -0.70% | -1.41% | 0.88% | -4.72% | -6.41% | -5.35% | -5.52% | -4.47% | 1.27% | 1.13% | 0.89% | 0.98% | 1.00% | 0.87% | 1.11% | 0.08% |
undefined analysts predict AGLE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Spyre Therapeutics's previous annual EBITDA (undefined) of $NaN.
Spyre Therapeutics Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 7 | 15 | 16 | 16 | 20 | 9 | 12 | 17 | 14 | 6 | 11 | 7 | 7 | 9 | 15 | 13 | 13 | 13 | 7 | 7 | 7 | 9 | 9 | 9 | 8 | 8 | 10 |
| Net Income | - | - | - | - | $-40.11M | $-217.08M | $-18.42M | $-18.82M | $-18.23M | $-22.32M | $-24.43M | $-20.31M | $-6.83M | $-18.22M | $-18.73M | $-21.50M | $-21.57M | $-18.02M | $-17.17M | $-11.92M | $-9.41M | $-8.12M | $-7.87M | $-6.63M | $-6.25M | $-6.24M | $-5.43M | $-4.55M |
| Avg Forecast | $147.31M | $128.30M | $-19.48M | $-0.52 | $-16.53M | $-31.88M | $-20.83M | $1.95 | $-17.68M | $-25.20M | $-22.28M | $-18.91M | $-4.75 | $-3.25 | $-21.03M | $-0.71 | $-14.00 | $-12.50 | $-12.50 | $-10.25 | $-7.43M | $-7.20M | $-8.88M | $-6.77M | $-6.25M | $-7.15M | $-4.91M | $-53.64M |
| High Forecast | $48.63M | $42.36M | $-15.58M | $-0.52 | $-13.22M | $-25.51M | $-16.67M | $3.27 | $-14.14M | $-20.16M | $-17.82M | $-15.13M | $-7.95 | $-5.44 | $-16.83M | $-0.85 | $-23.42 | $-20.91 | $-20.91 | $-17.15 | $-5.95M | $-5.76M | $-7.10M | $-5.42M | $-5.00M | $-5.72M | $-3.93M | $-42.91M |
| Low Forecast | $246.44M | $214.66M | $-23.37M | $-0.52 | $-19.83M | $-38.26M | $-25.00M | $0.65 | $-21.21M | $-30.24M | $-26.74M | $-22.69M | $-1.57 | $-1.07 | $-25.24M | $-0.57 | $-4.62 | $-4.13 | $-4.13 | $-3.38 | $-8.92M | $-8.64M | $-10.65M | $-8.12M | $-7.50M | $-8.57M | $-5.90M | $-64.36M |
| Surprise % | - | - | - | - | 2.43% | 6.81% | 0.88% | -9632943.01% | 1.03% | 0.89% | 1.10% | 1.07% | 1437894.74% | 5605538.46% | 0.89% | 30274647.89% | 1540928.57% | 1441520.00% | 1373360.00% | 1162634.15% | 1.27% | 1.13% | 0.89% | 0.98% | 1.00% | 0.87% | 1.11% | 0.08% |
Spyre Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AGLE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Spyre Therapeutics SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 7 | 15 | 16 | 16 | 20 | 9 | 12 | 17 | 14 | 6 | 11 | 7 | 7 | 9 | 15 | 13 | 13 | 13 | 7 | 7 | 7 | 9 | 9 | 9 | 8 | 8 | 10 |
| SG&A | - | - | - | - | $8.58M | $12.06M | $5.23M | $5.08M | $6.95M | $7.67M | $8.82M | $6.84M | $6.82M | $6.35M | $4.46M | $4.34M | $4.31M | $3.82M | $3.27M | $3.31M | $2.93M | $2.88M | $3.02M | $2.36M | $2.36M | $2.06M | $2.45M | $1.83M |
| Avg Forecast | - | - | $7.03M | $5.49M | $5.57M | $10.96M | $7.52M | $4.99M | $5.95M | $8.67M | $8.05M | $6.37M | $9.05M | $12.71M | - | $4.53M | $3.35M | $3.35M | $3.09M | $2.65M | $2.31M | $2.56M | $3.40M | $2.41M | $2.36M | $2.37M | $2.21M | $21.59M |
| High Forecast | - | - | $8.44M | $6.58M | $6.68M | $13.15M | $9.03M | $5.99M | $7.14M | $10.40M | $9.66M | $7.64M | $10.86M | $15.25M | - | $5.44M | $4.02M | $4.02M | $3.71M | $3.18M | $2.77M | $3.07M | $4.09M | $2.90M | $2.84M | $2.84M | $2.66M | $25.90M |
| Low Forecast | - | - | $5.63M | $4.39M | $4.45M | $8.77M | $6.02M | $3.99M | $4.76M | $6.93M | $6.44M | $5.09M | $7.24M | $10.17M | - | $3.63M | $2.68M | $2.68M | $2.47M | $2.12M | $1.85M | $2.05M | $2.72M | $1.93M | $1.89M | $1.89M | $1.77M | $17.27M |
| Surprise % | - | - | - | - | 1.54% | 1.10% | 0.69% | 1.02% | 1.17% | 0.89% | 1.10% | 1.07% | 0.75% | 0.50% | - | 0.96% | 1.29% | 1.14% | 1.06% | 1.25% | 1.27% | 1.13% | 0.89% | 0.98% | 1.00% | 0.87% | 1.11% | 0.08% |
Spyre Therapeutics's average Quarter SG&A projection for Dec 23 is $5.49M, based on 16 Wall Street analysts, with a range of $4.39M to $6.58M. The forecast indicates a -36.08% fall compared to AGLE last annual SG&A of $8.58M (Sep 23).
Spyre Therapeutics EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 7 | 15 | 16 | 16 | 20 | 9 | 12 | 17 | 14 | 6 | 11 | 7 | 7 | 9 | 15 | 13 | 13 | 13 | 7 | 7 | 7 | 9 | 9 | 9 | 8 | 8 | 10 |
| EPS | - | - | - | - | $-9.34 | $-0.00 | $-0.20 | $-0.22 | $-0.19 | $-0.27 | $-0.37 | $-0.31 | $-0.10 | $-0.28 | $-0.57 | $-0.67 | $-0.66 | $-0.55 | $-0.59 | $-0.54 | $-0.46 | $-0.49 | $-0.48 | $-0.47 | $-0.47 | $-0.47 | $-0.46 | $-0.40 |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $-27.68M | $-0.44 | $-4.50 | $-4.75 | $-25.16M | $-6.00 | $-6.50 | $-8.75 | $-7.25 | $-8.89M | $-36.42M | $-16.25 | $-22.88M | $-17.22M | $-16.34M | $-16.71M | $-9.79M | $-9.25 | $-13.50 | $-16.75 | $-14.75 | $-13.75 | $-16.75 | $-14.00 | $-5.54 |
| High Forecast | $0.51 | $0.44 | $0.52 | $-33.22M | $-0.44 | $-1.49 | $-1.57 | $-30.20M | $-1.98 | $-2.15 | $-2.89 | $-2.39 | $-10.67M | $-43.70M | $-5.37 | $-27.45M | $-20.67M | $-19.61M | $-20.05M | $-11.75M | $-3.05 | $-4.46 | $-5.53 | $-4.87 | $-4.54 | $-5.53 | $-4.62 | $-4.44 |
| Low Forecast | $2.58 | $2.25 | $2.64 | $-22.14M | $-0.44 | $-7.53 | $-7.95 | $-20.13M | $-10.04 | $-10.87 | $-14.64 | $-12.13 | $-7.11M | $-29.13M | $-27.19 | $-18.30M | $-13.78M | $-13.07M | $-13.37M | $-7.84M | $-15.48 | $-22.59 | $-28.02 | $-24.68 | $-23.00 | $-28.02 | $-23.42 | $-6.65 |
| Surprise % | - | - | - | - | 21.23% | 0.00% | 0.04% | 0.00% | 0.03% | 0.04% | 0.04% | 0.04% | 0.00% | 0.00% | 0.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.05% | 0.04% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.07% |
According to undefined Wall Street analysts, Spyre Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AGLE previous annual EPS of $NaN (undefined).
Spyre Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.04 | $5.50 | 13650.00% | Buy |
| XLO | Xilio Therapeutics | $0.81 | $7.00 | 764.20% | Buy |
| CTMX | CytomX Therapeutics | $1.20 | $5.77 | 380.83% | Buy |
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| NUVB | Nuvation Bio | $2.79 | $7.00 | 150.90% | Buy |
| DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
| ELYM | Eliem Therapeutics | $7.39 | $13.00 | 75.91% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| TIL | Instil Bio | $14.25 | $6.50 | -54.39% | Hold |
| AGLE | Spyre Therapeutics | $12.01 | $1.50 | -87.51% | Buy |
AGLE Forecast FAQ
Is Spyre Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Spyre Therapeutics (AGLE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of AGLE's total ratings.
What are Spyre Therapeutics's analysts' financial forecasts?
AGLE's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $9.88M (high $11.86M, low $7.9M), average EBITDA is $-62.506M (high $-47.81M, low $-77.202M), average net income is $-69.243M (high $-55.394M, low $-83.091M), average SG&A $29.54M (high $35.45M, low $23.63M), and average EPS is $-27.679M (high $-33.215M, low $-22.144M).
Did the AGLE's actual financial results beat the analysts' financial forecasts?
Based on Spyre Therapeutics's last annual report (Dec 2022), the company's revenue was $2.33M, which missed the average analysts forecast of $10.6M by -78.02%. Apple's EBITDA was $-84.781M, beating the average prediction of $-58.981M by 43.74%. The company's net income was $-83.815M, beating the average estimation of $-65.161M by 28.63%. Apple's SG&A was $28.53M, beating the average forecast of $27.65M by 3.17%. Lastly, the company's EPS was $-0.99, missing the average prediction of $-25.163M by -100.00%. In terms of the last quarterly report (Jun 2023), Spyre Therapeutics's revenue was $688K, missing the average analysts' forecast of $721.05K by -4.58%. The company's EBITDA was $-159M, beating the average prediction of $-31.362M by 407.76%. Spyre Therapeutics's net income was $-217M, beating the average estimation of $-31.882M by 580.88%. The company's SG&A was $12.06M, beating the average forecast of $10.96M by 10.04%. Lastly, the company's EPS was $-0.0023, missing the average prediction of $-4.5 by -99.95%